Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Winston-Salem, North Carolina 27157


Purpose:

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have advanced colorectal cancer.


Study summary:

OBJECTIVES: - Determine the response rate in patients with advanced colorectal cancer treated with gemcitabine. - Determine the toxic effects of this drug in these patients. - Determine the progression-free survival of patients treated with this drug. OUTLINE: This is a multicenter study. Patients receive gemcitabine IV continuously over 24 hours on days 1, 8, and 15. Treatment repeats every 28 days for a total of 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 months. PROJECTED ACCRUAL: A total of 12-41 patients will be accrued for this study within 2 years.


Criteria:

DISEASE CHARACTERISTICS: Histologically confirmed advanced colorectal cancer that has failed at least 1 prior course of fluoropyrimidine-based chemotherapy Measurable and/or evaluable disease PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - 0-2 Life expectancy: - At least 3 months Hematopoietic: - WBC at least 3,000/mm3 - Platelet count at least 100,000/mm3 Hepatic: - Bilirubin no greater than 2.5 times upper limit of normal (ULN) - ALT and/or AST no greater than 3 times ULN (no greater than 10 times ULN if - secondary to hepatic involvement by tumor Renal: - Creatinine no greater than 2.0 mg/dL Cardiovascular: - No history of cardiac arrhythmias requiring chronic treatment beyond an - acute event (e.g., arrhythmias during severe electrolyte abnormalities - allowed) - No active cardiac disease requiring treatment other than hypertension, - stable angina, or chronic valvular disease Other: - No other malignancy within the past 5 years except curatively treated - (including surgically cured) cancer - No serious medical or psychiatric illness that would preclude study - No active uncontrolled bacterial, fungal, or viral infection - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - See Disease Characteristics - No more than 3 prior chemotherapy regimens - Must have 1 prior fluorouracil-based regimen and 1 other cytotoxic agent - (e.g., irinotecan) - More than 4 weeks since prior chemotherapy - Prior gemcitabine allowed - No other concurrent antineoplastic therapy Endocrine therapy: - Not specified Radiotherapy: - More than 4 weeks since prior radiotherapy Surgery: - More than 4 weeks since prior surgery


NCT ID:

NCT00007943


Primary Contact:

Study Chair
Paul D. Savage, MD
Wake Forest University Health Sciences


Backup Contact:

N/A


Location Contact:

Winston-Salem, North Carolina 27157
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: September 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.